• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

识别心源性休克的生物标志物驱动亚表型:前瞻性队列和随机对照试验分析

Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials.

作者信息

Soussi Sabri, Tarvasmäki Tuukka, Kimmoun Antoine, Ahmadiankalati Mojtaba, Azibani Feriel, Dos Santos Claudia C, Duarte Kevin, Gayat Etienne, Jentzer Jacob C, Harjola Veli-Pekka, Hibbert Benjamin, Jung Christian, Johan Lassus, Levy Bruno, Lu Zihang, Lawler Patrick R, Marshall John C, Pöss Janine, Sadoune Malha, Nguyen Alexis, Raynor Alexandre, Peoc'h Katell, Thiele Holger, Mathew Rebecca, Mebazaa Alexandre

机构信息

Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.

University of Paris Cité, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France.

出版信息

EClinicalMedicine. 2024 Dec 18;79:103013. doi: 10.1016/j.eclinm.2024.103013. eCollection 2025 Jan.

DOI:10.1016/j.eclinm.2024.103013
PMID:39802301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11718329/
Abstract

BACKGROUND

Cardiogenic shock (CS) is a heterogeneous clinical syndrome, making it challenging to predict patient trajectory and response to treatment. This study aims to identify biological/molecular CS subphenotypes, evaluate their association with outcome, and explore their impact on heterogeneity of treatment effect (ShockCO-OP, NCT06376318).

METHODS

We used unsupervised clustering to integrate plasma biomarker data from two prospective cohorts of CS patients: CardShock (N = 205 [2010-2012, NCT01374867]) and the French and European Outcome reGistry in Intensive Care Units (FROG-ICU) (N = 228 [2011-2013, NCT01367093]) to determine the optimal number of classes. Thereafter, a simplified classifier (Euclidean distances) was used to assign the identified CS subphenotypes in three completed randomized controlled trials (RCTs) (OptimaCC, N = 57 [2011-2016, NCT01367743]; DOREMI, N = 192 [2017-2020, NCT03207165]; and CULPRIT-SHOCK, N = 434 [2013-2017, NCT01927549]) and explore heterogeneity of treatment effect with respect to 28-day mortality (primary outcome).

FINDINGS

Four biomarker-driven CS subphenotypes ('adaptive', 'non-inflammatory', 'cardiopathic', and 'inflammatory') were identified separately in the two cohorts. Patients in the inflammatory and cardiopathic subphenotypes had the highest 28-day mortality (p (log-rank test) = 0.0099 and 0.0055 in the CardShock and FROG-ICU cohorts, respectively). Subphenotype membership significantly improved risk stratification when added to traditional risk factors including the Society for Cardiovascular Angiography and Interventions (SCAI) shock stages (increase in Harrell's C-index by 4% ( = 0.033) and 6% ( = 0.0068) respectively in the CardShock and the FROG-ICU cohorts). The simplified classifier identified CS subphenotypes with similar biological/molecular and outcome characteristics in the three independent RCTs. No significant interaction was observed between treatment effect and subphenotypes.

INTERPRETATION

Subphenotypes with the highest concentration of biomarkers of endothelial dysfunction and inflammation (inflammatory) or myocardial injury/fibrosis (cardiopathic) were associated with mortality independently from the SCAI shock stages.

FUNDING

Dr Sabri Soussi was awarded the Canadian Institutes of Health Research (CIHR) Doctoral Foreign Study Award (DFSA) and the Merit Awards Program (Department of Anesthesiology and Pain Medicine, University of Toronto, Canada) for the current study.

摘要

背景

心源性休克(CS)是一种异质性临床综合征,这使得预测患者病程及对治疗的反应具有挑战性。本研究旨在识别生物学/分子层面的心源性休克亚表型,评估其与预后的关联,并探讨其对治疗效果异质性的影响(休克合作研究,NCT06376318)。

方法

我们采用无监督聚类方法,整合来自两个心源性休克患者前瞻性队列的数据:心脏休克队列(N = 205 [2010 - 2012年,NCT01374867])以及法国和欧洲重症监护病房结局注册研究(FROG - ICU)(N = 228 [2011 - 2013年,NCT01367093]),以确定最佳类别数量。此后,使用一种简化分类器(欧几里得距离)在三项完成的随机对照试验(RCT)中分配已识别的心源性休克亚表型(最佳心脏骤停后治疗,N = 57 [2011 - 2016年,NCT01367743];多模式心肺复苏与靶向温度管理试验,N = 192 [2017 - 2020年,NCT03207165];以及心源性休克罪犯血管血运重建术与最佳药物治疗试验,N = 434 [2013 - 2017年,NCT01927549]),并探讨28天死亡率(主要结局)方面的治疗效果异质性。

研究结果

在两个队列中分别识别出四种由生物标志物驱动的心源性休克亚表型(“适应性”、“非炎症性”、“心源性”和“炎症性”)。炎症性和心源性亚表型的患者28天死亡率最高(心脏休克队列中p(对数秩检验)= 0.0099,FROG - ICU队列中p = 0.0055)。当将亚表型归属添加到包括心血管造影和介入学会(SCAI)休克分期在内的传统危险因素中时,显著改善了风险分层(心脏休克队列和FROG - ICU队列中Harrell氏C指数分别增加4%(p = 0.033)和6%(p = 0.0068))。简化分类器在三项独立的随机对照试验中识别出具有相似生物学/分子及结局特征的心源性休克亚表型。未观察到治疗效果与亚表型之间存在显著相互作用。

解读

内皮功能障碍和炎症生物标志物浓度最高的亚表型(炎症性)或心肌损伤/纤维化亚表型(心源性)与死亡率相关,独立于SCAI休克分期。

资助情况

Sabri Soussi博士获得了加拿大卫生研究院(CIHR)博士国外研究奖(DFSA)以及(加拿大多伦多大学麻醉学与疼痛医学系)卓越奖计划,用于当前研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/35ec38a0474b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/2f7a4a59bf21/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/c6eac837ff57/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/4243afc0c3b8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/2e0766e51a8b/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/35ec38a0474b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/2f7a4a59bf21/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/c6eac837ff57/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/4243afc0c3b8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/2e0766e51a8b/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/528e/11718329/35ec38a0474b/gr5.jpg

相似文献

1
Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials.识别心源性休克的生物标志物驱动亚表型:前瞻性队列和随机对照试验分析
EClinicalMedicine. 2024 Dec 18;79:103013. doi: 10.1016/j.eclinm.2024.103013. eCollection 2025 Jan.
2
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis.基于机器学习模型的临床数据对 ARDS 亚表型的验证和实用性:一项观察性、多队列、回顾性分析。
Lancet Respir Med. 2022 Apr;10(4):367-377. doi: 10.1016/S2213-2600(21)00461-6. Epub 2022 Jan 10.
3
Inflammatory subphenotypes previously identified in ARDS are associated with mortality at intensive care unit discharge: a secondary analysis of a prospective observational study.先前在急性呼吸窘迫综合征中确定的炎症亚表型与重症监护病房出院时的死亡率相关:一项前瞻性观察研究的二次分析。
Crit Care. 2024 May 7;28(1):151. doi: 10.1186/s13054-024-04929-9.
4
Sepsis subphenotyping based on organ dysfunction trajectory.基于器官功能轨迹的脓毒症亚表型分型。
Crit Care. 2022 Jul 3;26(1):197. doi: 10.1186/s13054-022-04071-4.
5
Clinical phenotypes of cardiogenic shock survivors: insights into late host responses and long-term outcomes.心源性休克幸存者的临床表型:对晚期宿主反应和长期结局的深入了解。
ESC Heart Fail. 2024 Apr;11(2):1242-1248. doi: 10.1002/ehf2.14596. Epub 2023 Dec 4.
6
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause - the Cardiogenic Shock Score.无论病因如何,对心源性休克患者进行早期风险分层——心源性休克评分。
Eur J Heart Fail. 2022 Apr;24(4):657-667. doi: 10.1002/ejhf.2449. Epub 2022 Feb 14.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts.COVID-19 相关急性呼吸窘迫综合征患者的纵向呼吸亚表型:来自三个观察队列的结果。
Lancet Respir Med. 2021 Dec;9(12):1377-1386. doi: 10.1016/S2213-2600(21)00365-9. Epub 2021 Oct 13.
9
Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study.基于潜在类别分析的亚表型可推广至急性呼吸窘迫综合征的观察队列:一项前瞻性研究。
Thorax. 2022 Jan;77(1):13-21. doi: 10.1136/thoraxjnl-2021-217158. Epub 2021 Jul 12.
10
Identification and validation of robust hospital-acquired pneumonia subphenotypes associated with all-cause mortality: a multi-cohort derivation and validation.与全因死亡率相关的医院获得性肺炎稳健亚表型的识别与验证:多队列推导与验证
Intensive Care Med. 2025 Apr;51(4):692-707. doi: 10.1007/s00134-025-07884-3. Epub 2025 Apr 22.

引用本文的文献

1
Cardiogenic shock: diagnosis, phenotyping and management.心源性休克:诊断、分型及管理
Intensive Care Med. 2025 Aug 6. doi: 10.1007/s00134-025-08049-y.
2
Cardiogenic shock syndrome unraveled: understanding the different layers of heterogeneity.解析心源性休克综合征:理解其异质性的不同层面
Intensive Care Med. 2025 Jul 14. doi: 10.1007/s00134-025-08021-w.
3
Inflammatory Indices in Patients with Myocardial Infarction Complicated by Cardiogenic Shock, and Their Interconnections with SCAI Stages and Patients' Survival: A Retrospective Study.

本文引用的文献

1
Management of cardiogenic shock: state-of-the-art.心原性休克的治疗:最新进展。
Intensive Care Med. 2024 Nov;50(11):1814-1829. doi: 10.1007/s00134-024-07618-x. Epub 2024 Sep 10.
2
Advances in the Staging and Phenotyping of Cardiogenic Shock: Part 1 of 2.心源性休克分期与表型分析的进展:系列文章第1部分(共2部分)
JACC Adv. 2022 Oct 28;1(4):100120. doi: 10.1016/j.jacadv.2022.100120. eCollection 2022 Oct.
3
Machine Learning Approaches for Phenotyping in Cardiogenic Shock and Critical Illness: Part 2 of 2.用于心源性休克和危重症表型分析的机器学习方法:第2部分(共2部分)
心肌梗死合并心源性休克患者的炎症指标及其与SCAI分期和患者生存的相关性:一项回顾性研究
J Clin Med. 2025 Jun 16;14(12):4283. doi: 10.3390/jcm14124283.
4
AI-Based Predictive Models for Cardiogenic Shock in STEMI: Real-World Data for Early Risk Assessment and Prognostic Insights.基于人工智能的ST段抬高型心肌梗死心源性休克预测模型:早期风险评估和预后洞察的真实世界数据
J Clin Med. 2025 May 25;14(11):3698. doi: 10.3390/jcm14113698.
5
Dynamic Predictive Models of Cardiogenic Shock in STEMI: Focus on Interventional and Critical Care Phases.ST段抬高型心肌梗死中心源性休克的动态预测模型:聚焦于介入治疗和重症监护阶段
J Clin Med. 2025 May 16;14(10):3503. doi: 10.3390/jcm14103503.
6
Comparison of different AI systems for diagnosing sepsis, septic shock, and cardiogenic shock: a retrospective study.用于诊断脓毒症、脓毒性休克和心源性休克的不同人工智能系统的比较:一项回顾性研究。
Sci Rep. 2025 May 6;15(1):15850. doi: 10.1038/s41598-025-00830-9.
JACC Adv. 2022 Oct 28;1(4):100126. doi: 10.1016/j.jacadv.2022.100126. eCollection 2022 Oct.
4
Extending the 'host response' paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities.将“宿主反应”范式从脓毒症扩展到心源性休克:证据、局限性和机会。
Crit Care. 2023 Nov 27;27(1):460. doi: 10.1186/s13054-023-04752-8.
5
Identification of molecular subphenotypes in two cohorts of paediatric ARDS.在两个儿科 ARDS 队列中鉴定分子亚表型。
Thorax. 2024 Jan 18;79(2):128-134. doi: 10.1136/thorax-2023-220130.
6
Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials.鉴定脓毒症的分子表型:两项前瞻性观察队列研究的分析和两项随机对照试验的二次分析。
Lancet Respir Med. 2023 Nov;11(11):965-974. doi: 10.1016/S2213-2600(23)00237-0. Epub 2023 Aug 23.
7
Precision Medicine in Cardiogenic Shock: We Are Almost There!心源性休克中的精准医学:我们已近在咫尺!
JACC Heart Fail. 2023 Oct;11(10):1316-1319. doi: 10.1016/j.jchf.2023.06.024. Epub 2023 Aug 16.
8
Clinical Course of Patients in Cardiogenic Shock Stratified by Phenotype.根据表型分层的心源性休克患者的临床病程
JACC Heart Fail. 2023 Oct;11(10):1304-1315. doi: 10.1016/j.jchf.2023.05.007. Epub 2023 Jun 21.
9
Cardiogenic shock: a major challenge for the clinical trialist.心原性休克:临床试验研究者面临的重大挑战。
Curr Opin Crit Care. 2023 Aug 1;29(4):371-380. doi: 10.1097/MCC.0000000000001066. Epub 2023 Jun 19.
10
Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: analyses of the phase II adrenomedullin and outcome in septic shock 2 trial.富集策略对脓毒性休克患者接受阿祖单抗治疗结局的影响:II期肾上腺髓质素与脓毒性休克2试验结局分析
Front Med (Lausanne). 2022 Dec 1;9:1058235. doi: 10.3389/fmed.2022.1058235. eCollection 2022.